CN110638844A - Compound microecological preparation for preventing type 2 diabetes of pets and application thereof - Google Patents
Compound microecological preparation for preventing type 2 diabetes of pets and application thereof Download PDFInfo
- Publication number
- CN110638844A CN110638844A CN201911003071.6A CN201911003071A CN110638844A CN 110638844 A CN110638844 A CN 110638844A CN 201911003071 A CN201911003071 A CN 201911003071A CN 110638844 A CN110638844 A CN 110638844A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- diabetes
- lactobacillus
- pets
- lactobacillus paracasei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 150000001875 compounds Chemical class 0.000 title claims description 14
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 34
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 32
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 32
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 31
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 31
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 31
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 25
- 241001468229 Bifidobacterium thermophilum Species 0.000 claims abstract description 25
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 25
- 239000006041 probiotic Substances 0.000 claims abstract description 19
- 235000018291 probiotics Nutrition 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 230000000529 probiotic effect Effects 0.000 claims abstract description 14
- 229920001202 Inulin Polymers 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 12
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 12
- 229940029339 inulin Drugs 0.000 claims abstract description 12
- 241000186000 Bifidobacterium Species 0.000 claims description 17
- 230000004083 survival effect Effects 0.000 claims description 17
- 239000003833 bile salt Substances 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 210000004211 gastric acid Anatomy 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 10
- 241000282326 Felis catus Species 0.000 claims description 6
- 241000282472 Canis lupus familiaris Species 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000000968 intestinal effect Effects 0.000 abstract description 18
- 239000002131 composite material Substances 0.000 abstract description 11
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 6
- 208000037976 chronic inflammation Diseases 0.000 abstract description 4
- 230000006020 chronic inflammation Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000012807 shake-flask culturing Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
The invention discloses a composite microecological preparation for preventing type 2 diabetes of pets and application thereof, wherein the preparation comprises a probiotic mixture, and the balance of probiotic mixture is complemented by xylooligosaccharide and inulin, wherein the addition mass ratio of the xylooligosaccharide to the inulin is 1: 1; the probiotic mixture comprises bifidobacterium animalis, lactobacillus casei, lactobacillus paracasei, bifidobacterium thermophilum and bifidobacterium longum, and the number ratio of the bifidobacterium animalis to the lactobacillus casei to the lactobacillus paracasei to the bifidobacterium thermophilum to the bifidobacterium longum is 1:1:1:1: 1. The bifidobacterium animalis, the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium thermophilum, the bifidobacterium longum, the inulin and the xylooligosaccharide contained in the composite microecological preparation have synergistic effects of increasing intestinal probiotics and regulating the balance of intestinal flora, are mainly used for preventing T2DM of pets, and simultaneously have the functions of improving the intestinal flora, reducing the generation of chronic inflammation, promoting health, improving the immunity of organisms and preventing and improving insulin resistance, thereby having the function of preventing type 2 diabetes of pets.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a composite microecological preparation for preventing type 2 diabetes of pets and application thereof.
Background
Diabetes is a metabolic disorder disease caused by lack of insulin, and is easy to occur to obese middle-aged and old-aged dogs and cats. The diabetes of pets is classified into type 1, type 2 and type 3. Type 1 diabetes is also called insulin-dependent diabetes, and diseased dogs and cats usually cannot secrete insulin because pancreatic beta cells are dysplastic or damaged, and need to be treated with insulin for a lifetime. Type 2 diabetes is also called non-insulin dependent diabetes mellitus, and the impaired sensitivity and reduced number of receptors on insulin target cells usually cause insulin resistance and cell dysfunction in sick dogs and cats, resulting in relative insulin deficiency. Type 2 diabetes is most likely to occur in cats. Type 3 diabetes, also known as secondary diabetes, often results in insulin antagonism and glucose intolerance due to damage to the islets from inflammation and surgery among other known diseases. Type 2 diabetes is caused by obesity due to lack of exercise and excessive food intake of pets, besides heredity. Research shows that the intestinal flora of diabetics has increased abundance of harmful bacteria such as Enterobacteriaceae bacteria and the like, and decreased abundance of beneficial bacteria such as bifidobacteria, lactic acid bacteria and the like. Thus regulating intestinal flora can improve blood sugar level of diabetic patients. At present, probiotics or prebiotics are adopted to improve and correct intestinal flora of diabetics, and clinical tests have achieved certain effects. However, at present, there is no probiotic for pets for preventing or improving type 2 diabetes.
Research shows that the increase of the expression level of the chronic inflammatory factor is one of the causes of type 2 diabetes caused by insulin resistance, and the intestinal flora in obese hosts is remarkably changed and is related to the generation of the chronic inflammation, so that the prevention of diabetes and the improvement of blood sugar of obese pets are extremely important.
Disclosure of Invention
The invention aims to provide a compound microecological preparation for preventing type 2 diabetes of pets, which can increase intestinal probiotics, regulate the balance of intestinal flora, prevent and improve insulin resistance, and an application thereof.
In order to achieve the purpose, the invention provides the following technical scheme: the compound microecological preparation for preventing type 2 diabetes of pets is characterized in that: comprises a probiotic mixture, and the balance of the probiotic mixture is complemented by xylo-oligosaccharide and inulin, wherein the adding mass ratio of the xylo-oligosaccharide to the inulin is 1: 1; the probiotic mixture comprises bifidobacterium animalis, lactobacillus casei, lactobacillus paracasei, bifidobacterium thermophilum and bifidobacterium longum, and the number ratio of the bifidobacterium animalis to the lactobacillus casei to the lactobacillus paracasei to the bifidobacterium thermophilum to the bifidobacterium longum is 1:1:1:1: 1.
Further, the viable count of the animal bifidobacterium strain is more than or equal to 2.0 multiplied by 1010CFU/g, the viable count of lactobacillus casei is more than or equal to 2.0 multiplied by 1010CFU/g, the viable count of lactobacillus paracasei is more than or equal to 2.0 multiplied by 1010CFU/g, the number of viable bifidobacterium thermophilum is more than or equal to 2.0 multiplied by 1010CFU/g, number of viable bacteria of Bifidobacterium longum is not less than 2.0 × 1010CFU/g。
Further, the survival rate of the lactobacillus casei and the lactobacillus paracasei is more than 60 percent when the lactobacillus casei and the lactobacillus paracasei are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.
Further, the survival rate of the animal bifidobacterium, the thermophilic bifidobacterium and the bifidobacterium longum is more than 50 percent when the animal bifidobacterium, the thermophilic bifidobacterium and the bifidobacterium longum are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.
Furthermore, the survival rates of the strains of the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are all more than 20 percent when the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are cultured in 0.2 percent of No. 3 bile salt for 2 hours.
The invention also aims to provide an application of the composite microecological preparation for preventing the type 2 diabetes of pets, and the composite microecological preparation is used for preventing the type 2 diabetes of pets caused by obesity.
Compared with the prior art, the invention has the beneficial effects that: the bifidobacterium animalis, the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium thermophilum, the bifidobacterium longum, the inulin and the xylooligosaccharide contained in the composite microecological preparation have synergistic effects of increasing intestinal probiotics and regulating the balance of intestinal flora, are mainly used for preventing T2DM of pets, and simultaneously have the functions of improving the intestinal flora, reducing the generation of chronic inflammation, promoting health, improving the immunity of organisms and preventing and improving insulin resistance, thereby having the function of preventing type 2 diabetes of pets.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A composite microecological preparation for preventing type 2 diabetes of pets comprises probiotic mixture, and xylooligosaccharide and inulin in balance, wherein the addition mass ratio of xylooligosaccharide to inulin is 1: 1; the probiotic mixture comprises bifidobacterium animalis, lactobacillus casei, lactobacillus paracasei, bifidobacterium thermophilum and bifidobacterium longum, and the number ratio of the bifidobacterium animalis to the lactobacillus casei to the lactobacillus paracasei to the bifidobacterium thermophilum to the bifidobacterium longum is 1:1:1: 1.
The number of viable bacteria of Bifidobacterium animalis strain is not less than 2.0 × 1010CFU/g, the viable count of lactobacillus casei is more than or equal to 2.0 multiplied by 1010CFU/g, the viable count of lactobacillus paracasei is more than or equal to 2.0 multiplied by 1010CFU/g, the number of viable bifidobacterium thermophilum is more than or equal to 2.0 multiplied by 1010CFU/g, number of viable bacteria of Bifidobacterium longum is not less than 2.0 × 1010CFU/g。
The survival rate of the lactobacillus casei and the lactobacillus paracasei is more than 60 percent when the lactobacillus casei and the lactobacillus paracasei are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.
The survival rate of the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum is more than 50 percent when the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.
The survival rates of the strains are all more than 20 percent when the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are cultured in 0.2 percent of No. 3 bile salt for 2 hours.
The application of the composite microecological preparation for preventing the type 2 diabetes of pets is used for preventing the type 2 diabetes of pets, which is caused by obesity, of dogs and cats.
Example 2
The invention provides a research on the acid and bile salt resistance of five strains of a composite microecological preparation for preventing type 2 diabetes of pets, which comprises the following specific steps:
(1) the study on the acid resistance and the bile salt resistance of bifidobacterium animalis, bifidobacterium thermophilum and bifidobacterium longum comprises the following steps: the operation method of 3 strains is the same, taking bifidobacterium animalis strain as an example, 5ml of sterile water is added into 1 strain slant test tube, slant colonies are washed off, mixed uniformly, inoculated into a shake flask culture medium according to the inoculum size of 1 percent, and subjected to static culture at 37 ℃ for 14-16 h;
preparation of shake flask culture medium: the shake flask culture medium comprises the following raw materials in percentage by mass: glucose 1.0%, yeast extract powder 1.0%, peptone 0.5%, tryptone 0.5%, L-cysteine hydrochloride 0.05%, and trace salt 4%, adjusting pH to 7.4, and sterilizing at 115 deg.C for 20 min.
The trace salt formula comprises: 0.2g/LCaCl2，0.48g/LMgSO4，10g/LNaHCO3，1.0g/LKH2PO4，1.0g/LK2HPO4，2.0g/LNaCl；
Acid resistance characteristic study: adding the bacterial liquid into artificial gastric juice with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0 h, 1 h and 2h respectively to determine the survival rate of the bacterial strain.
Study of bile salt resistance: adding the bacterial liquid into artificial intestinal juice containing 0.2% of No. 3 bile salt in an inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0 h, 1 h and 2h respectively to determine the survival rate of the bacterial strain.
(2) The study on the acid resistance and the bile salt resistance of lactobacillus casei and lactobacillus paracasei comprises the following steps: the operation method of 2 strains is the same, taking lactobacillus casei as an example, 5ml of sterile water is added into 1 strain slant test tube, slant colonies are washed off, mixed evenly, inoculated into a shake flask culture medium according to the inoculum size of 1 percent, and subjected to static culture at 37 ℃ for 14-16 h;
preparation of shake flask culture medium: the shake flask culture medium comprises the following raw materials in percentage by mass: glucose 1.0%, yeast extract powder 1.0%, peptone 0.5%, tryptone 0.5%, L-cysteine hydrochloride 0.05%, and trace salt 4%, adjusting pH to 7.0, and sterilizing at 115 deg.C for 20 min.
The trace salt formula comprises: 0.2g/LCaCl2，0.48g/LMgSO4，10g/LNaHCO3，1.0g/LKH2PO4，1.0g/LK2HPO4，2.0g/LNaCl；
Acid resistance characteristic study: adding the bacterial liquid into artificial gastric juice with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0 h, 1 h and 2h respectively to determine the survival rate of the bacterial strain.
Study of bile salt resistance: adding the bacterial liquid into artificial intestinal juice containing 0.2% of No. 3 bile salt in an inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0 h, 1 h and 2h respectively to determine the survival rate of the bacterial strain.
The results of the acid resistance study of the strains are detailed in the following table 1:
TABLE 1 Probiotics survival Rate in Artificial gastric juice
As can be seen from the above Table 1, Lactobacillus casei and Lactobacillus paracasei have good gastric acid resistance, and the survival rate of the Lactobacillus paracasei and Lactobacillus paracasei is still higher than 60% when the Lactobacillus paracasei and Lactobacillus paracasei are cultured in gastric acid with the pH of 3.0 for 2 hours. The gastric acid resistance of animal bifidobacterium strains, thermophilic bifidobacterium and bifidobacterium longum is slightly poor, but the survival rate of the animal bifidobacterium strains, the thermophilic bifidobacterium and the bifidobacterium longum reaches 50 percent when the animal bifidobacterium strains, the thermophilic bifidobacterium and the bifidobacterium longum are cultured in gastric acid with the pH of 3.0 for 2 hours. The five strains are shown to have better gastric acid tolerance property, can resist gastric acid and can survive in a large amount.
The results of the study on the bile salt resistance of the strains are shown in the following table 2:
TABLE 2 results of treatment of artificial intestinal fluids (containing bile salts)
As can be seen from the above table 2, the survival rate of the Bifidobacterium animalis strain, Lactobacillus casei, Lactobacillus paracasei, Bifidobacterium thermophilum and Bifidobacterium longum is higher than 20% when the Bifidobacterium animalis strain, the Lactobacillus casei, the Lactobacillus paracasei, the Bifidobacterium thermophilum and the Bifidobacterium longum are cultured in 0.2% of No. 3 bile salt for 2 hours, and the Bifidobacterium animalis strain has certain bile salt resistance.
Example 3
The influence of the compound microecological preparation on the blood sugar of the T2DMSD rat is tested;
animal experiments are adopted to observe whether the composite microecologics have the effect of improving the blood sugar level of the T2DMSD rat. The composite microecological preparation used in the test comprises animal bifidobacterium strain with the viable count more than or equal to 2.0 x 1010CFU/g, the number of viable lactobacillus casei is more than or equal to 2.0 x 1010CFU/g, the number of viable lactobacillus paracasei is more than or equal to 2.0 x 1010CFU/g, the number of viable bifidobacterium thermophilum is more than or equal to 2.0 x 1010CFU/g, number of viable bacteria of Bifidobacterium longum is not less than 2.0 x 1010CFU/g, and the balance being respectively complemented by xylo-oligosaccharide and inulin, wherein the mass ratio of the xylo-oligosaccharide to the inulin is 1: 1.
The animal experiment is carried out on 18 mice in total. A first group: t2DMSD rat complex probiotics treatment group; second group: untreated control group of T2DMSD rats; third group: SD rat healthy control group. Each group had 6. Fasting blood glucose and postprandial 2h blood glucose were measured.
The administration scheme is as follows: treatment groups: the compound microecologics are taken by T2DMSD rats after drinking water, 1 time respectively in the morning and evening every day, and are continuously used for 30 days; untreated controls of T2DMSD rats: no medication was given; blank control group: no medication was used. After 30 days, the fasting blood sugar and the postprandial blood sugar of SD rats are measured, and the effect of the compound microecological preparation on improving the blood sugar of diabetes is investigated.
The clinical observation and treatment statistics of the treatment group, the disease untreated control group and the healthy control group are shown in tables 3 and 4;
table 3 shows fasting blood glucose
Table 4 shows the 2h postprandial blood glucose profile
As can be seen from the above tables 3 and 4, the fasting blood glucose value is 67% of the normality rate of the treated group, the fasting blood glucose value of the untreated group is 7.0mmol/L higher than the normal value, and the blood glucose of the SD rat of the healthy control group is normal; the blood sugar value after 2 hours of meal, the treatment group and the disease untreated group are both out of the normal value of 11.1mmol/L, and the table shows that the blood sugar of the T2DM rat has the function of reducing the blood sugar after continuously taking for 30 days, but the blood sugar can not completely reach the normal value. The continuous taking or the combination treatment of the medicine can achieve better effect, therefore, the invention can be used for preventing the type 2 diabetes of the pet so as to reduce the occurrence of the type 2 diabetes of the pet.
The bifidobacterium animalis strain, the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium thermophilum and the bifidobacterium longum screened out by the method are all original bacteria in intestinal tracts of healthy animals, and have the probiotic effect of enhancing the immunity of the animal body and adjusting the balance of the intestinal flora;
the invention is specially used for preventing obese pets from causing type 2 diabetes due to insulin resistance caused by imbalance of intestinal flora. After the T2DMSD rat is treated by the compound microecological preparation, the fasting blood glucose can be improved, so the preparation is mainly used for preventing the T2DM of pets. Meanwhile, the traditional Chinese medicine composition has the functions of improving intestinal flora, reducing the generation of chronic inflammation, promoting health and improving the immunity of organisms.
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes in the embodiments and/or modifications of the invention can be made, and equivalents and modifications of some features of the invention can be made without departing from the spirit and scope of the invention.
Claims (6)
1. The compound microecological preparation for preventing type 2 diabetes of pets is characterized in that: comprises a probiotic mixture, and the balance of the probiotic mixture is complemented by xylo-oligosaccharide and inulin, wherein the adding mass ratio of the xylo-oligosaccharide to the inulin is 1: 1; the probiotic mixture comprises bifidobacterium animalis, lactobacillus casei, lactobacillus paracasei, bifidobacterium thermophilum and bifidobacterium longum, and the number ratio of the bifidobacterium animalis to the lactobacillus casei to the lactobacillus paracasei to the bifidobacterium thermophilum to the bifidobacterium longum is 1:1:1:1: 1.
2. The complex microecological formulation according to claim 1, wherein the inhibitor comprises a compound of formula i: the number of viable bacteria of Bifidobacterium animalis strain is not less than 2.0 × 1010CFU/g, the viable count of lactobacillus casei is more than or equal to 2.0 multiplied by 1010CFU/g, the viable count of lactobacillus paracasei is more than or equal to 2.0 multiplied by 1010CFU/g, the number of viable bifidobacterium thermophilum is more than or equal to 2.0 multiplied by 1010CFU/g, number of viable bacteria of Bifidobacterium longum is not less than 2.0 × 1010CFU/g。
3. The complex microecological formulation according to claim 1, wherein the inhibitor comprises a compound of formula i: the survival rate of the lactobacillus casei and the lactobacillus paracasei is more than 60 percent when the lactobacillus casei and the lactobacillus paracasei are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.
4. The complex microecological formulation according to claim 1, wherein the inhibitor comprises a compound of formula i: the survival rate of the animal bifidobacterium, the thermophilic bifidobacterium and the bifidobacterium longum is more than 50 percent when the animal bifidobacterium, the thermophilic bifidobacterium and the bifidobacterium longum are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.
5. The complex microecological formulation according to claim 1, wherein the inhibitor comprises a compound of formula i: the survival rates of the strains of the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are all more than 20 percent when the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are cultured in 0.2 percent of No. 3 bile salt for 2 hours.
6. The use of the complex probiotic for the prevention of type 2 diabetes in pets according to claim 1, characterized in that: the compound microecological preparation is used for preventing type 2 diabetes caused by obesity of pet dogs and cats.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911003071.6A CN110638844A (en) | 2019-10-22 | 2019-10-22 | Compound microecological preparation for preventing type 2 diabetes of pets and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911003071.6A CN110638844A (en) | 2019-10-22 | 2019-10-22 | Compound microecological preparation for preventing type 2 diabetes of pets and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110638844A true CN110638844A (en) | 2020-01-03 |
Family
ID=68994438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911003071.6A Pending CN110638844A (en) | 2019-10-22 | 2019-10-22 | Compound microecological preparation for preventing type 2 diabetes of pets and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110638844A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0859492A (en) * | 1994-08-26 | 1996-03-05 | Yakult Honsha Co Ltd | Antidiabetic drug |
| US20110268702A1 (en) * | 2008-05-16 | 2011-11-03 | Nestec S.A. | Lactobacillus paracasei and weight control |
| US20140079676A1 (en) * | 2012-09-20 | 2014-03-20 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| CN108157973A (en) * | 2017-12-14 | 2018-06-15 | 上海交通大学医学院附属瑞金医院 | The probiotic composition and its preparation of a kind of beneficial glycolipid metabolism function and application |
-
2019
- 2019-10-22 CN CN201911003071.6A patent/CN110638844A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0859492A (en) * | 1994-08-26 | 1996-03-05 | Yakult Honsha Co Ltd | Antidiabetic drug |
| US20110268702A1 (en) * | 2008-05-16 | 2011-11-03 | Nestec S.A. | Lactobacillus paracasei and weight control |
| US20140079676A1 (en) * | 2012-09-20 | 2014-03-20 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| CN108157973A (en) * | 2017-12-14 | 2018-06-15 | 上海交通大学医学院附属瑞金医院 | The probiotic composition and its preparation of a kind of beneficial glycolipid metabolism function and application |
Non-Patent Citations (1)
| Title |
|---|
| 薛静静等: "肠道菌群与2型糖尿病关系的研究进展", 《山东医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006253007B2 (en) | Feline probiotic Bifidobacteria | |
| JP5905032B2 (en) | Synbiotic composition for recovery and reconstitution of intestinal microbiota | |
| CN102326678B (en) | Penta-composite probiotic powder preparation and preparation method thereof | |
| CN114317353B (en) | Lactobacillus plantarum ZJFFYJ 7 and application thereof | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| US20220031769A1 (en) | Strain for preventing and treating metabolic diseases and use thereof | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN113583903A (en) | Microbial composition for preventing or treating type II diabetes and preparation method and application thereof | |
| CN116077536B (en) | Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof | |
| CN110623984A (en) | Quadruple viable bacteria preparation for treating diarrhea and application thereof | |
| CN111493261A (en) | Probiotic solid beverage for relieving or treating constipation symptom | |
| CN115011532B (en) | Lactobacillus paracasei JY062 preparation, and preparation method and application thereof | |
| CN110200156A (en) | It is a kind of improve feed intake piglet mixed feed additive and application | |
| CN116622587B (en) | Probiotic prepared by synthetic biological method, composition and application thereof | |
| CN109136151B (en) | Compound lactobacillus plantarum preparation with blood sugar reducing function and application thereof | |
| CN114933984B (en) | Probiotic and prebiotic composite composition for promoting in-vivo plasticizer and heavy metal discharge and preparation method thereof | |
| CN110638844A (en) | Compound microecological preparation for preventing type 2 diabetes of pets and application thereof | |
| CN115044507B (en) | Microbial composition for treating and/or preventing abnormal glycolipid metabolism and application thereof | |
| CN117603828A (en) | Lactobacillus rhamnosus LRa66 with blood glucose and blood lipid reducing functions and application thereof | |
| CN110638841A (en) | Probiotics and prebiotics compound preparation, preparation method and application thereof | |
| CN116211900A (en) | Microecological viable bacteria preparation for improving polycystic ovary syndrome, and preparation method and application thereof | |
| US20240000864A1 (en) | Bacillus coagulans having blood glucose reduction efficacy, and application thereof | |
| CN109364085A (en) | Bletilla striata oligosaccharides and combinations thereof is adjusting the application in glucose -lipid metabolism disorder | |
| CN101028290A (en) | Probiotics preparation for decreasing human-body or fowl and animal serum cholesterol and its process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200103 |
|
| RJ01 | Rejection of invention patent application after publication |